UVA develops new and faster method to track superbugs

University of Virginia Health System researchers are the first in the world to develop a new and faster method to track major infection-causing "superbugs" - a major key in preventing the spread of deadly infections.

Their research, published in the November/December 2011 issue of the online journal mBio, comes at a critical time.

Several newly discovered genes such as KPC (Klebsiella pneumoniae carbapenemase) and NDM (New Delhi metallo-betalactamase) have experts on alert for several reasons:

-their ability to easily transform bacteria into antibiotic-resistant superbugs
-their unprecedented ability to cross over into different strains and species of bacteria
-the ease with which they can transfer to highly infectious bacteria, such as Salmonella and cholera and
-the potential for these genes to easily establish themselves undetected in our environment.

"When you're in a race against time to halt the spread of these life-threatening infections, the traditional methods of detection and tracking are very difficult and frankly take too long," says UVA Medical Center Epidemiologist Costi Sifri, MD, study principal investigator.

Decoding deadly hospital-acquired infections

The focus of their study was KPC, a gene Sifri calls "perhaps the most important new resistance gene of the millennium." KPC has the ability to easily hitch a ride on movable genetic elements called plasmids that then spread between pathogens, making them highly infectious and deadly.

Through their new method, Sifri's research team was able to quickly track the movement of plasmids carrying KPC between bacteria and understand the spread of KPC bacteria at the molecular level.

While traditional methods take several weeks or months to do this analysis and can only be performed in specialized research laboratories, the method developed by the UVA team takes only one to two days and can be performed by most modern microbiology laboratories.

"We developed and successfully used a novel technique to rapidly track the gene's movement between patients and bacteria," says lead author Dr. Amy Mathers, assistant professor in the UVA School of Medicine's Division of Infectious Diseases and International Health.

"We were able to show that all cases in a cluster of hospital infections could be traced back to a single patient. Most cases were linked by movement of the KPC gene between different bacteria."

Armed with this information, the research team hopes to develop new strategies and tools to prevent the spread of these highly resistant bacteria to other patients.

The pathogens associated with this new gene are called CRE, or Carbapenem- Resistant Enterobacteriaceae, and include E. coli and Klebsiella, among others. Infections caused by CRE are associated with very high mortality rates, Sifri says.

A global health threat

"These pathogens are widely considered a major healthcare threat in the United States and worldwide," says Sifri. "Monitoring their origin and spread is critical to preventing serious outbreaks in hospitals, other healthcare facilities, and potentially the general population."

In fact, another drug resistance gene called NDM emerged last year as a cause of significant disease in India and may be acquired through drinking water. The pathogen spread quickly and was carried to the U.S. and Great Britain.

"Carbapenems have become essential antibiotics for the treatment of many infections in hospitals today, and their potential loss as a reliably effective class of antibiotics is a serious public health threat," Sifri says. "The more rapidly we can detect CRE and understand movement of KPC gene in hospitalized patients, the more quickly we can intervene to prevent CRE spread to other patients and bacteria. This is fundamentally important for maintaining the effectiveness of this important class of antibiotics."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers uncover key genes linked to DCIS progression